LongCovid_Emblem
Topics
Meeting category
Date(s)
21 Nov 2024 - 22 Nov 2024
Program Language
English
Location
Barcelona, Spain
Meeting type
Hybrid
CME credits
8
Virology Education

Demystifying Long COVID International Conference 2024

Related Enduring Materials

Enduring Materials
Thursday, 21 November
Opening & Welcome - 14:00
14:10 CET
Opening Talk: Long COVID: State of the Science and Directions for Policy and Research
Roger Paredes, MD, PhD
Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain
Session 1: Clinical Spectrum - Different Faces of Long COVID -
14:40 CET
Epidemiology and Long Term Evolution of Long COVID
Olivier Robineau, MD, PhD
Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France
15:05 CET
Autonomic Dysfunction in long COVID
Nicola Montano, PhD
University of Milan, Italy
15:30 CET
Long COVID in Children
Danilo Buonsenso, MD, PhD
Gemelli University Hospital, Italy
Session 2: Abstract-Driven Session -
16:30 CET
#1 - Clinical Insights From a Pediatric Long COVID Clinic
Sindhu Mohanadas
United States
16:42 CET
#2 - Impact of Persistent Symptoms on Quality of Life in Long COVID Patients: A Comparative Study
David Lerma Irureta
Spain
16:55 CET
#3 - Long COVID and Associated Outcomes Following COVID-19 Reinfections: Insights from an International Patient-Led Survey
Gina Assaf & Leticia Soares
United States
17:07 CET
#4 - An Innovative Digital Health Solution to Address Unmet Needs in Long COVID: Results From the Co-design Study of the Long COVID Companion App
Aurélie Fischer & Pauline Oustric
France
Session 3: Patient-Centred Coordination of Care - Where Do We Stand? -
17:20 CET
Dutch Example
Mischa Huson, MD, PhD, DTM&H
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
17:30 CET
Spanish Example
Lourdes Mateu, MD, PhD
Germans Trias i Pujol Hospital, Spain
17:40 CET
French Example
Jérôme Larché, MD, MSc
Clinique du Parc, France
Friday, 22 November
Session 4: Pathophysiology -
08:30 CET
Immune Dysregulation and Autoimmunity in Long COVID
Daniel M. Altmann, PhD
Imperial College London, United Kingdom
08:55 CET
Viral Reservoirs and Consequences of SARS-CoV-2 Persistence
Morgane Bomsel, PhD
Institut Cochin, Paris, France
09:20 CET
#5 - Persistent Immune Dysregulation and Metabolic Alterations Following SARS-CoV-2 Infection
Irini Sereti
United States
09:32 CET
#6 - Unraveling the Molecular Signature of Long COVID with Post-Exertional Fatigue: An Analysis of Circulating Proteomic and Metabolomic Profiles
Marta Massanella
Spain
09:44 CET
#7 - Sub-maximal 2-day Cardiopulmonary Exercise Testing to Assess Exercise Tolerance and Symptom Responses in People with Long COVID
Callum Thomas
United Kingdom
Session 5: Diagnostics, Biomarkers, and End Points -
10:20 CET
Molecular PET imaging of long COVID
Eric Guedj, MD, Dipl.-Ing, PhD
Aix-Marseille University / Timone Hospital / Fresnel Institute, France
10:45 CET
Tomorrow, and Tomorrow, and Tomorrow... Studies of the Neuropathogenesis of Long COVID
Serena Spudich, MD
Yale University, United States
11:10 CET
#8 - Normalization of Cognitive Function in Patients With Neurological Symptoms Post COVID-19 After 12 Months
Siv Elin Pignatiello
Norway
11:22 CET
#9 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
Spain
Session 6: Illustrating the Challenges - Clinical Case Presentations -
13:35 CET
Case 1: Differential Diagnosis
Gemma Lladós, MD
Hospital Germans Trias i Pujol, Spain
14:00 CET
Case 2: No Cure, What Are the Options
Clara Lehmann, MD
University of Cologne, Germany
Session 7: Clinical Trials - Prevention and Treatment Options on the Horizon -
14:55 CET
Long Covid Therapeutic Trials: Current Status
Dominique Salmon, MD, PhD
Institut Fournier, France
15:20 CET
What Have We Learned from Observational Studies to Improve Future Clinical Trials
Igho Ofotokun, MD, MSc, FIDSA
Emory University, United States
15:45 CET
Viral Persistence and Long COVID: Lessons Learned from the First Round of Clinical Trials
Michael Peluso, MD
University of California, San Francisco, United States
16:10 CET
#10 - Anticoagulant and Antiviral Therapy in Long COVID: A Real-World Prospective Cohort Study and Grassroots Patient-Designed Trial
Johan Van Weyenbergh
Belgium
16:22 CET
#11 - Exploring the Efficacy of Plasma Exchange Therapy in Post-COVID-19 Condition: A Pilot Randomized Double-Blind Trial
Sergio España Cueto
Spain
16:35 CET
Patient Perspective on Clinical Trials Design
Chantal Britt, MA
Long Covid Switzerland, Switzerland

End of the Program

Language
Ratings previous edition
The activity was well-planned
4.9
(126)
Content is relevant to my practice
4.7
(126)
Content was presented clearly
4.8
(126)
Content was free from commercial bias
4.3
(126)